Many people believe that the myth of “The Greatest Showman” is true. Parkinson’s diseaseAlthough the condition is most common in the elderly, it has been found that more middle-aged individuals are suffering from the neurodegenerative disorder. According to the National Parkinson Foundation, 10 percent of Parkinson’s patients are diagnosed before they reach 40.
There are many effective treatments for Parkinson’s disease, including brain stimulation and exercise. However, diagnostic tests and curative treatment options still have a lot to do.
“Existing approved therapies only treat the symptoms of Parkinson’s,”Gerald E. Commissiong, President and CEO of Amarantus BioScience Holdings, Inc., (OTCQB,AMBS), a biotechnology company that focuses on developing new treatments for neurodegenerative diseases. “A therapeutic protein called MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) has shown the potential to rejuvenate dying cells and protect the neurons that produce dopamine in rodents.”
Parkinson’s disease is part of the motor system disorder category. This means that brain cells that produce dopamine are dying. Symptoms include trembling of the limbs and faces, stiffness in your torso and torso and slow movement.
Commissiong believes that the therapeutic MANF program offered by Amarantus could prevent Parkinson’s disease from getting worse, and may even restore normal cell function. It is essential to be able to prevent cell death, also known as apoptosis. It could be used for treating Alzheimer’s disease, stroke, and traumatic brain injury (TBIs).
Amarantus is a publicly traded company that also develops a platform for diagnosing Alzheimer’s, Lou Gehrigs disease, breast cancer, and Parkinson’s.
You can learn more about Amarantus’ therapeutic MANF program by visiting www.amarantus.com.
